2 Stocks to Buy With Less Than $40
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look exciting, and all for the price of a few breakfast items. As long as investors hold on to these companies' shares for a while and add to their positions regularly, strong returns await them.That said, let's discuss two stocks, each of which is trading for less than $40, that are worth investors' serious consideration: Viking Therapeutics (NASDAQ: VKTX) and Exelixis (NASDAQ: EXEL).Viking is still just a clinical-stage drugmaker. It hasn't even started a phase 3 study yet. But don't underestimate this rising star in the biotech industry. It has delivered better mid-stage results than most in the sea of prominent (and not-so-prominent) drugmakers looking to dip their toes in the fast-growing weight loss market. The company's VK2735 produced excellent data in phase 2 clinical trials.Continue reading
Some think investing in stocks requires substantial start-up capital, but that's false. Even with a modest sum, like $40, investors can acquire shares of companies whose long-term prospects look exciting, and all for the price of a few breakfast items. As long as investors hold on to these companies' shares for a while and add to their positions regularly, strong returns await them.
That said, let's discuss two stocks, each of which is trading for less than $40, that are worth investors' serious consideration: Viking Therapeutics (NASDAQ: VKTX) and Exelixis (NASDAQ: EXEL).
Viking is still just a clinical-stage drugmaker. It hasn't even started a phase 3 study yet. But don't underestimate this rising star in the biotech industry. It has delivered better mid-stage results than most in the sea of prominent (and not-so-prominent) drugmakers looking to dip their toes in the fast-growing weight loss market. The company's VK2735 produced excellent data in phase 2 clinical trials.
